Gilead Sciences (GILD) Intangibles (2009 - 2026)
Gilead Sciences (GILD) posted Intangibles of $16.4 billion for Q1 2026, down 3.51% quarter-over-quarter from $17.0 billion in Q4 2025, and down 15.36% year-on-year from $19.4 billion in Q1 2025.
Gilead Sciences (GILD) Intangibles (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has reported Intangibles for 18 consecutive years, with $16.4 billion the latest figure, recorded in Q1 2026.
- Intangibles for Q1 2026 came in at $16.4 billion, down 15.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.4 billion (down 15.36% YoY), and the FY2025 annual result was $17.0 billion, down 14.89% from the prior year.
- Intangibles was $16.4 billion for Q1 2026 at Gilead Sciences, down from $17.0 billion in the prior quarter.
- Over five years, Intangibles peaked at $30.3 billion in Q1 2022 and troughed at $16.4 billion in Q1 2026.
- Average Intangibles over 5 years is $23.8 billion, with a median of $23.4 billion recorded in 2024.
- Year-over-year, Intangibles declined 6.54% in 2023 and fell 24.59% in 2024.
- Over 5 years, Intangibles stood at $28.9 billion in 2022, then dropped by 8.44% to $26.5 billion in 2023, then retreated by 24.59% to $19.9 billion in 2024, then decreased by 14.89% to $17.0 billion in 2025, then decreased by 3.51% to $16.4 billion in 2026.
- Per Business Quant data, the three most recent Intangibles figures were $16.4 billion in Q1 2026, $17.0 billion in Q4 2025, and $18.0 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.37 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 49.06 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 50.87 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 36.91 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 25.75 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 21.38 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 16.38 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 52.56 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 11.30 Bn |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 9.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.38 Bn |
| Dec 31, 2025 | 16.98 Bn |
| Sep 30, 2025 | 17.97 Bn |
| Jun 30, 2025 | 18.57 Bn |
| Mar 31, 2025 | 19.36 Bn |
| Dec 31, 2024 | 19.95 Bn |
| Sep 30, 2024 | 20.55 Bn |
| Jun 30, 2024 | 22.83 Bn |
| Mar 31, 2024 | 23.43 Bn |
| Dec 31, 2023 | 26.45 Bn |
| Sep 30, 2023 | 27.15 Bn |
| Jun 30, 2023 | 27.75 Bn |
| Mar 31, 2023 | 28.35 Bn |
| Dec 31, 2022 | 28.89 Bn |
| Sep 30, 2022 | 29.44 Bn |
| Jun 30, 2022 | 29.89 Bn |
| Mar 31, 2022 | 30.33 Bn |
| Dec 31, 2021 | 33.46 Bn |
| Sep 30, 2021 | 33.90 Bn |
| Jun 30, 2021 | 34.34 Bn |